Millennium Management’s Teva Pharmaceuticals TEVA Stock Holding History

Millennium Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.2M	Buy	604,200 +547,000	+956%	+$17.6M	0.01%	1634
2025 Q4	$1.79M	Sell	57,200 -360,800	-86%	-$8.89M	﹤0.01%	4044
2025 Q3	$8.44M	Buy	418,000 +315,000	+306%	+$5.53M	﹤0.01%	2566
2025 Q2	$1.73M	Buy	103,000 +47,000	+84%	+$758K	﹤0.01%	4010
2025 Q1	$861K	Sell	56,000 -90,000	-62%	-$1.61M	﹤0.01%	4468
2024 Q4	$3.22M	Buy	146,000 +123,700	+555%	+$2.25M	﹤0.01%	3239
2024 Q3	$402K	Sell	22,300 -19,400	-47%	-$340K	﹤0.01%	5000
2024 Q2	$678K	Sell	41,700 -8,100	-16%	-$125K	﹤0.01%	4397
2024 Q1	$703K	Sell	49,800 -207,000	-81%	-$2.61M	﹤0.01%	4580
2023 Q4	$2.68M	Buy	256,800 +50,000	+24%	+$467K	﹤0.01%	3361
2023 Q3	$2.11M	Sell	206,800 -175,000	-46%	-$1.63M	﹤0.01%	3505
2023 Q2	$2.87M	Buy	381,800 +1,000	+0.3%	+$8.11K	﹤0.01%	3164
2023 Q1	$3.37M	Sell	380,800 -475,300	-56%	-$4.7M	﹤0.01%	2956
2022 Q4	$7.81M	Sell	856,100 -2,394,200	-74%	-$20.9M	﹤0.01%	2393
2022 Q3	$26.2M	Buy	3,250,300 +31,200	+1%	+$276K	0.02%	1095
2022 Q2	$24.2M	Sell	3,219,100 -1,194,900	-27%	-$10.4M	0.02%	1132
2022 Q1	$41.4M	Buy	4,414,000 +2,148,500	+95%	+$17.9M	0.02%	801
2021 Q4	$18.1M	Sell	2,265,500 -58,100	-3%	-$524K	0.01%	1532
2021 Q3	$22.6M	Buy	2,323,600 +2,023,600	+675%	+$18.9M	0.01%	1217
2021 Q2	$2.97M	Buy	+300,000	New	+$3.18M	﹤0.01%	3453
2021 Q1	–	Sell	-4,065,200	Closed	-$39.2M	–	6504
2020 Q4	$39.2M	Buy	+4,065,200	New	+$38.9M	0.03%	593
2020 Q3	–	Sell	-600,000	Closed	-$7.4M	–	4817
2020 Q2	$7.4M	Buy	+600,000	New	+$6.79M	0.01%	1448
2020 Q1	–	Sell	-520,000	Closed	-$5.1M	–	4463
2019 Q4	$5.1M	Buy	+520,000	New	+$4.64M	0.01%	1918
2019 Q3	–	Sell	-100,000	Closed	-$923K	–	4551
2019 Q2	$923K	Sell	100,000 -300,000	-75%	-$3.62M	﹤0.01%	2855
2019 Q1	$6.27M	Buy	+400,000	New	+$7.05M	0.01%	1600
2018 Q4	–	Sell	-75,000	Closed	-$1.62M	–	4167
2018 Q3	$1.62M	Sell	75,000 -125,000	-63%	-$2.9M	﹤0.01%	2586
2018 Q2	$4.86M	Buy	+200,000	New	+$4.08M	0.01%	1835
2017 Q1	–	Sell	-330,000	Closed	-$12M	–	3829
2016 Q4	$12M	Buy	+330,000	New	+$13.2M	0.03%	823
2016 Q3	–	Sell	-100,000	Closed	-$5.02M	–	3597
2016 Q2	$5.02M	Hold	100,000	–	–	0.01%	1258
2016 Q1	$5.35M	Hold	100,000	–	–	0.01%	1214
2015 Q4	$6.56M	Buy	+100,000	New	+$6.18M	0.01%	1180
2015 Q2	–	Sell	-330,000	Closed	-$20.6M	–	3827
2015 Q1	$20.6M	Buy	330,000 +230,000	+230%	+$13.4M	0.04%	650
2014 Q4	$5.75M	Hold	100,000	–	–	0.01%	1295
2014 Q3	$5.38M	Hold	100,000	–	–	0.01%	1250
2014 Q2	$5.24M	Sell	100,000 -854,800	-90%	-$43.7M	0.01%	1190
2014 Q1	$50.5M	Buy	954,800 +874,400	+1,088%	+$40.4M	0.15%	146
2013 Q4	$3.22M	Buy	+80,400	New	+$3.17M	0.01%	1481
2013 Q3	–	Sell	-96,300	Closed	-$3.77M	–	3563
2013 Q2	$3.77M	Buy	+96,300	New	+$3.75M	0.01%	1198

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's TEVA Position: Q1 2026 in Review

Millennium Management opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 1,893,845 shares worth $57M. The stake represents 0.02% of the portfolio and ranks #753 among its holdings. This is a return to the name: Millennium Management previously reported a position in TEVA as recently as Q3 2025.

Millennium Management first reported a position in TEVA in Q2 2013 and has held it in 51 quarters since. The position peaked at $560M in Q1 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Millennium Management held 1,893,845 shares of Teva Pharmaceuticals worth $57M as of Q1 2026.
Teva Pharmaceuticals was a new Millennium Management position in Q1 2026.
Teva Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #753 holding.
Millennium Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Millennium Management's Teva Pharmaceuticals position peaked at $560M in Q1 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.